What is Leerink Partnrs' Estimate for STOK FY2027 Earnings?

Key Points

• Leerink Partners increased their FY2027 earnings estimate for Stoke Therapeutics to ($2.35) per share, up from the previous estimate of ($3.10).
• Stoke Therapeutics recently reported quarterly earnings of ($0.40) per share, beating analysts' consensus estimates of ($0.57).
• The stock has an average rating of "Buy" from analysts, with a median price target of $25.57.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Leerink Partnrs boosted their FY2027 earnings estimates for shares of Stoke Therapeutics in a report issued on Monday, October 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($2.35) for the year, up from their previous estimate of ($3.10). The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics' FY2028 earnings at ($2.80) EPS and FY2029 earnings at ($0.40) EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million.

Other research analysts have also issued reports about the company. Wedbush lifted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Stoke Therapeutics in a research note on Wednesday. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They issued a "buy" rating and a $30.00 price target on the stock. BTIG Research set a $28.00 price target on shares of Stoke Therapeutics and gave the stock a "buy" rating in a research report on Monday, August 18th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $25.57.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $30.50 on Thursday. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $32.40. The stock has a market cap of $1.67 billion, a PE ratio of 35.88 and a beta of 1.24. The business's fifty day moving average is $20.29 and its 200-day moving average is $13.52.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 10,000 shares of the company's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total value of $250,700.00. Following the completion of the sale, the general counsel directly owned 11,831 shares in the company, valued at approximately $296,603.17. This represents a 45.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 5,501 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the sale, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. The trade was a 22.95% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 160,180 shares of company stock worth $3,379,406. Corporate insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Siren L.L.C. lifted its holdings in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after acquiring an additional 247,347 shares during the period. GAMMA Investing LLC lifted its position in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after buying an additional 5,084 shares during the period. Invesco Ltd. boosted its stake in Stoke Therapeutics by 117.0% in the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company's stock valued at $174,000 after buying an additional 14,118 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Stoke Therapeutics in the 1st quarter valued at $2,376,000. Finally, Nuveen LLC acquired a new stake in Stoke Therapeutics in the 1st quarter valued at $719,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.